Skip to Main Content
Contribute Try STAT+ Today

After more than five years of litigation, Bayer (BAYRY) and Johnson & Johnson (JNJ) agreed to pay $775 million to settle about 25,000 lawsuits over claims they failed to warn about side effects associated with the Xarelto blood thinner, which the companies jointly market.

The settlement, which will be split evenly between the drug makers, resolves both federal and state cases that alleged the companies downplayed potentially fatal risks of internal bleeding and aggressively marketed the drug as an alternative to warfarin for people who sought to avoid blood clots. Neither of the companies admitted liability, although both noted they prevailed in six cases that went to trial.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.